BPC-157: What the Research Shows, and What It Doesn't

In 2026, BPC-157 drew a run of headlines: a vote by a federal advisory panel and a change on the FDA's compounding lists. Many articles go further than the evidence supports. Below is what the primary sources actually document.

For laboratory research use only. Not for human or veterinary use. Nothing here is medical advice.

What BPC-157 is

BPC-157 is a synthetic peptide made of 15 amino acids.[4] In its 2026 briefing document, the FDA says it "is reported to be a pentadecapeptide fragment of BPC" that "has been found in gastric juice." The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its molecular formula is C62H98N16O22, and its molecular weight is 1419.5 g/mol, a figure PubChem also lists (CID 9941957).[1][2]

Where the research stands

Most of the published research is preclinical, meaning studies in cells and animals rather than people.

• A 2025 systematic review in HSS Journal included 36 studies. Of those, "35 preclinical studies, 1 clinical study." It also states: "No clinical safety data were found."[3]
• A 2025 review in Current Reviews in Musculoskeletal Medicine notes that "only three pilot studies have examined BPC-157 in humans." It concludes that the compound "should be considered investigational."[4]
• In its own literature search, the FDA found five small clinical studies. It noted that they "were of short duration, had small sample sizes, evaluated doses that were likely exploratory in nature," and gave "limited information on safety data." Two of the five were reported only as meeting abstracts.[1]
• ClinicalTrials.gov lists a handful of registered studies. They include a 2015 phase 1 study whose status is listed as unknown, and two newer studies that are recruiting or have not yet started (searched October 11, 2026).[5]

A reader of the FDA's reference list will notice that many of the nonclinical papers come from the same research group.[1]

The FDA's 2026 review

Category 2. The FDA keeps a list of bulk substances that may present "significant safety risks" in compounding. BPC-157's nominators withdrew it from that list, and the FDA page (current as of April 22, 2026) now lists BPC-157 under "nominated but withdrawn" with the agency's concerns still attached. The agency's note is worth reading in full: compounded BPC-157 "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization," and the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans."[6]

The advisory committee. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee discussed whether to add BPC-157 to the 503A bulks list, which lists substances pharmacies may compound from.[7] FDA staff concluded that "a balancing of the criteria weighs against" listing it.[1] The committee voted 8 to 6, with one abstention, in favor,[8] against the staff recommendation in the briefing.[1] News reports note that the vote is non-binding and needs FDA sign-off.[8]

Where that leaves it. As of October 11, 2026, we found no final rule in the Federal Register that adds BPC-157 to the 503A bulks list.[9] It is not an FDA-approved drug. It is also prohibited in sport under the World Anti-Doping Agency's S0 "non-approved substances" category.[10]

What the regulators flagged

The FDA's briefing raises quality questions that matter to anyone who handles research material:

• Characterization. BPC-157 is "considered not well-characterized from the physical and chemical characterization perspective." Data were lacking or inadequate on "peptide-related impurities and aggregates, microbial quality (bioburden, bacterial endotoxins)."[1]
• Impurities and aggregation. Of the acetate form: "We cannot rule out the potential for immunogenicity associated with these impurities and peptide-related aggregates."[1]

There are a few things to keep in mind when reading a certificate of analysis: what was tested, how it was tested, and what wasn't tested. Our research section explains how to read one.

The short version

• A 15-amino-acid synthetic peptide, researched mainly in animals.
• Human data come from only a few small, short-term studies.
• Its nominators withdrew it from the FDA's Category 2 list, and the FDA page still shows it there under "nominated but withdrawn" with the agency's concerns. In July 2026 an advisory committee voted 8 to 6 in favor of adding it to the 503A bulks list; the vote is not binding. As of October 11, 2026, we found no final rule, and it is not approved.
• The FDA's documents raise concerns about impurities, aggregation and how well it is characterized.

For laboratory research use only. Not for human or veterinary use, diagnostic, or therapeutic purposes.

Sources (fetched October 11, 2026)

1. FDA briefing document, Pharmacy Compounding Advisory Committee, BPC-157: https://www.fda.gov/media/193343/download
2. PubChem CID 9941957: https://pubchem.ncbi.nlm.nih.gov/compound/9941957
3. Vasireddi et al., HSS Journal, 2025. PMID 40756949: https://pubmed.ncbi.nlm.nih.gov/40756949/
4. McGuire et al., Curr Rev Musculoskelet Med, 2025. PMID 40789979: https://pubmed.ncbi.nlm.nih.gov/40789979/
5. ClinicalTrials.gov search "BPC-157": https://clinicaltrials.gov/search?term=BPC-157 (the three BPC-157-specific entries: NCT02637284, NCT07437547, NCT07803250)
6. FDA, "Certain bulk drug substances for use in compounding that may present significant safety risks": https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
7. FDA, July 23-24, 2026 PCAC meeting: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
8. ABC News on the PCAC vote: https://abcnews.com/Health/fda-advisory-committee-votes-add-popular-peptide-bpc/story?id=134913891
9. Federal Register search, "BPC-157", October 11, 2026: https://www.federalregister.gov/documents/search?conditions%5Bterm%5D=%22BPC-157%22
10. USADA, "BPC-157 peptide prohibited": https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/